Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG:2335)

HKG:2335 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-153.58	-153.58	-125.83
Net Income Net Income Growth	-182.51	-182.51	-154.63
Earnings Per Share EPS Growth	-0.75	-0.75	-0.66
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	236.07	236.07	179.81
Total Debt Total Debt Growth	1,209	1,209	74.89
Net Cash (Debt) Net Cash Growth	-972.65	-972.65	104.93
Net Cash Growth	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-4.00	-4.00	0.45

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-137.13	-137.13	-107.74
Capital Expenditures CapEx Growth	-0.88	-0.88	-1.3
Free Cash Flow Free Cash Flow Growth	-138.01	-138.01	-109.04
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 26, 2026

Data Sources Report a data error